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Abstract: Asenapine tablets are a new option for the treatment of schizophrenia. Sublingual 
administration is essential because bioavailability if ingested is less than 2%. Efficacy is sup-
ported by acute and long-term randomized controlled studies conducted by the manufacturer, 
with asenapine 5 mg twice daily evidencing superiority over placebo in six-week studies of 
acute schizophrenia, and flexibly-dosed asenapine (modal dose 10 mg twice daily) superior 
to placebo in a 26-week maintenance of response study. Tolerability advantages over some 
second-generation antipsychotics, such as olanzapine, include a relatively favorable weight 
and metabolic profile, as demonstrated in a 52-week randomized, head-to-head, double-blind 
clinical trial. Although dose-related extrapyramidal symptoms and akathisia can be present, the 
frequency of these effects is lower than that for haloperidol and risperidone. Somnolence may 
also occur, and appears to be somewhat dose-dependent when examining rates of this among 
patients receiving asenapine for schizophrenia and bipolar disorder. Prolactin elevation can 
occur, but at a rate lower than that observed for haloperidol or risperidone. Unique to asenapine 
is the possibility of oral hypoesthesia, occurring in about 5% of participants in the clinical trials. 
Obstacles to the use of asenapine are the recommendations for twice-daily dosing and the need 
to avoid food or liquids for 10 minutes after administration, although the bioavailability is only 
minimally reduced if food or liquids are avoided for only two minutes.
Keywords: antipsychotic, asenapine, clinical trials, schizophrenia
Introduction
Schizophrenia is a relatively common mental disorder that is usually chronic in 
nature. Interventions are ordinarily targeted to positive psychotic symptoms such as 
hallucinations or delusions, but negative, cognitive, and mood symptoms can also be 
disabling. There is an array of antipsychotic medications currently available, distin-
guishable principally by their safety and tolerability profiles, although some differences 
in efficacy also exist when groups of patients are compared in randomized controlled 
trials.1 The individual person with schizophrenia may respond to, or tolerate, one 
antipsychotic but not another, in a manner that is not predictable, lending to empirical 
trials of different agents when treating the illness in the clinic. The quest is to identify 
a particular medication that works “well enough”, is tolerated “well enough”, and that 
the patient is willing to adhere to.
Asenapine was initially approved by the US Food and Drug Administration (FDA) 
in 2009 for the treatment of acute schizophrenia and acute manic or mixed episodes 
associated with bipolar I disorder in adults, and subsequently received approval for the 
maintenance phase of schizophrenia and for adjunctive use with lithium or valproate Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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for acute manic or mixed episodes associated with bipolar I 
disorder.2 A literature search using the key word “asenapine” 
with no limitations or constraints was undertaken on April 6, 
2011 using PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) 
and Embase (http://www.embase.com/), yielding 67 and 212 
records, respectively. Abstracted from the search results 
were all studies or analyses of asenapine for the treatment of 
schizophrenia. The PubMed search resulted in five clinical 
trial reports involving patients with schizophrenia,3–8 includ-
ing a QT study.7,8 The Embase search produced six additional 
relevant citations to abstracts from presentations at medical 
conferences.9–14 Abstracts from the most recent meeting of 
the American College of Neuropsychopharmacology, held 
on December 5–9, 2010 were also accessed as published, 
resulting in three additional citations.15–17 Also queried 
was http://www.clinicaltrials.gov for completed trials with 
results available on the website for asenapine in patients 
with schizophrenia.18–24 This review is based on those reports 
and the contents of the most current US product labeling,2 
together with additional information that can be found in the 
author’s prior review,25 as well as in documents available 
on the FDA website.26–28 In total, six short-term and seven 
longer-term randomized controlled studies of asenapine for 
the treatment of schizophrenia are included in this review, 
as outlined in Tables 1 and 2.
Pharmacokinetics and 
pharmacodynamics
Asenapine is unique among the currently available antipsy-
chotics in that it is a fast-dissolving tablet that is absorbed 
primarily in the oral mucosa. If swallowed, the bioavail-
ability of asenapine is limited to less than 2% because of 
high hepatogastrointestinal first-pass metabolism.2,26 Patient 
instructions are to place the tablet under the tongue and not 
to eat or drink for 10 minutes after administration.2 The 
highly porous tablets, available in 5 mg and 10 mg strengths, 
dissolve in the saliva within approximately 10 seconds, and 
result in bioavailability of approximately 35%.2,26,27 Drinking 
water sooner than 10 minutes after administration of sublin-
gual asenapine can reduce its bioavailability,2,26 with a 19% 
reduction in plasma exposure observed following water 
administration at two minutes. If placed elsewhere in the oral 
cavity, asenapine will still be absorbed, as demonstrated in 
an open-label, randomized, three-way crossover trial among 
healthy men who received single 5 mg doses of asenapine 
via sublingual, supralingual, and buccal routes,29 where with 
buccal administration (ie, “cheeking”) the plasma level expo-
sure was almost 25% higher than for the sublingual route, 
and 6% lower with supralingual administration than with 
sublingual administration. These differences in exposure are 
smaller than the overall variability observed in studies, where 
overall exposure varied by 37%, with a mean interindividual 
variability of 26% and a mean intraindividual variability of 
26%.26 Increasing the dose from 5 mg to 10 mg twice daily 
(a two-fold increase) results in less than linear (1.7 times) 
increases in both the extent of exposure and maximum 
concentration.2
Peak plasma levels occur rapidly, within 30–90 minutes.2,26,27 
The mean terminal half-life is approximately 24 hours.2 
Metabolism is primarily through direct glucuronidation by 
UGT1A4 and oxidative metabolism by cytochrome P450 
(CYP) isoenzymes (predominantly CYP1A2).2 Asenap-
ine has a large volume of distribution (approximately 
20–25 L/kg) and is highly bound (95%) to plasma proteins, 
including albumin and α1-acid glycoprotein.2 Despite the fact 
that smoking can induce CYP1A2, concomitant smoking had 
no substantial effect on the pharmacokinetics of asenapine 
when tested in healthy male subjects.2 Fluvoxamine, a potent 
CYP1A2 inhibitor, can increase exposure to asenapine by 
29%,2 and should be coadministered with caution.2 Asenapine 
is not recommended in patients with severe hepatic impair-
ment because asenapine exposures were on average seven 
times higher than for patients with normal hepatic function.2 
No dosage adjustment is required for patients with renal 
impairment.2 Asenapine can inhibit CYP2D6 and result in 
two-fold increases in paroxetine concentrations.26 Although 
not yet studied in a clinical trial, CYP2D6 inhibition may 
be of clinical importance when combing asenapine with 
CYP2D6-dependent antipsychotics,25 and the product label-
ing advises caution when coadministering asenapine with 
drugs that are both substrates and inhibitors for CYP2D6.2
Asenapine is the active moiety, and although there are 
approximately 38 metabolites, none are highly prevalent, 
and the metabolites have few relevant effects because of their 
lower affinity for the relevant receptors or because of their 
inability to cross the blood–brain barrier.25,26
Although the precise mechanism of action of asenapine 
in the treatment of schizophrenia is unknown, it is thought 
that antagonism at the dopamine D2 and serotonin 5HT2A 
receptors mediates antipsychotic activity.2 Asenapine has a 
unique receptor binding profile.30 The receptor binding profile 
in order of Ki values (in nM) is: 5-HT2C (0.03) . 5-HT2A 
(0.06) . 5-HT7 (0.13) . 5-HT2B (0.16) . 5-HT6 (0.25) . D3 
(0.42) . H1 (1.0) . D4 (1.1) . NE alpha 1 (1.2) = NE alpha 
2 (1.2) . D2 (1.3) . D1 (1.4) . 5-HT5 (1.6) . 5-HTA 
(2.5) . 5-HT1B (4.0) . H2 (6.2) ..   muscarinic M1 (8128). Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Sublingual asenapine for schizophrenia
Asenapine is functionally an antagonist at the above receptors. 
The differing   receptor affinity “fingerprints” of the available 
antipsychotics can potentially explain their heterogeneity 
in terms of their efficacy and tolerability profiles, and can 
explain in part the heterogeneity of antipsychotic response 
from patient to patient.31 It is noted that asenapine appears to 
have relatively higher potency at serotonin receptors than at 
dopamine   receptors, including the serotonin HT7 receptor, 
which has been studied regarding object discrimination in 
rats,32 and may be a therapeutic target for achieving antide-
pressant and memory-enhancing actions.33 Receptor binding 
affinities may also help in predicting potential tolerability. 
For example, because of the noradrenergic alpha 1 receptor 
antagonism, asenapine can add to the effect of certain anti-
hypertensive agents.2 Moreover, antagonism of histamine H1 
receptors appears to be associated with the sedative effects 
of asenapine.26
As a caveat, receptor signatures are ordinarily quanti-
fied using cloned human receptors, and actual correla-
tions with observed clinical effects needs to be assessed in 
people. Positron emission tomography can be used to do this,34 
and asenapine has demonstrated dose-dependent dopamine D2 
receptor occupancy (dose range 0.1–4.8 mg), with a significant 
correlation between D2 occupancy and plasma concentration.26 
Sublingual administration of 4.8 mg twice daily resulted in 
high levels of D2 occupancy, with a mean occupancy of 79% 
at approximately 3–6 hours after dosing.26
Efficacy in schizophrenia
Short-term efficacy
Short-term efficacy for schizophrenia was tested in four piv-
otal six-week, randomized, double-blind, placebo-controlled 
and active comparator-controlled multicenter studies that 
included asenapine doses of 5 mg or 10 mg twice daily 
(Table 1). Two studies were accepted by the FDA as sup-
portive of asenapine’s efficacy in the acute treatment of 
schizophrenia in adults.3,4 The other two studies consisted of 
one negative trial (study 41021; asenapine 5 mg twice daily 
and 10 mg twice daily did not statistically significantly sepa-
rate from placebo on the primary outcome measure, but the 
active control, ie, olanzapine 15 mg/day, did) and one failed 
trial (study 41022; asenapine flexibly dosed at 5 mg or 10 mg 
twice daily did not statistically significantly separate from 
placebo on the primary outcome measure and neither did the 
active control of olanzapine flexibly dosed at 10–20 mg/day).26 
Although these two latter unpublished trials could not be used 
to establish efficacy, the safety and tolerability outcomes were 
included in an integrated safety database.
In one of the positive trials, 458 patients with acute 
schizophrenia were randomly assigned to fixed-dose treat-
ment with asenapine at 5 mg twice daily, asenapine at 10 mg 
twice daily (after one day at 5 mg twice daily), placebo, or 
an active control for assay sensitivity, ie, haloperidol at 4 mg 
twice daily.3 The study was international in scope and took 
place in 2005–2006. Patients were required to be hospitalized 
during the first two weeks of the study. The primary efficacy 
endpoint was change from baseline in the total score on the 
Positive and Negative Syndrome Scale (PANSS). There were 
two prespecified methodological approaches to assess effi-
cacy, ie, analysis of covariance using last observation carried 
forward (LOCF) as the primary analysis and a mixed model 
for repeated measures (MMRM) as the secondary analysis. 
Discontinuation rates were 37.6%, 33.3%, 42.0%, and 43.4% 
for asenapine 5 mg twice daily, asenapine 10 mg twice daily, 
haloperidol, and placebo groups, respectively. The discon-
tinuation rates due to insufficient therapeutic response were 
12.8%, 16.2%, 8.9%, and 25.4%, respectively, yielding a 
number needed to treat (number needed to treat [NNT] = 35, 
see Figure 1) versus placebo to avoid discontinuation because 
of an insufficient therapeutic response of 8, 11, and 7 for 
asenapine 5 mg twice daily, asenapine 10 mg twice daily, 
and haloperidol, respectively. On both LOCF and MMRM 
analyses of change in PANSS total score, asenapine 5 mg 
twice daily and haloperidol were both superior to placebo, 
with statistically significant differences seen from day 21 
onwards. However, asenapine 10 mg twice daily showed 
no advantage over placebo at any time point on the LOCF 
analysis and an advantage only at day 42 on the MMRM 
analysis, an effect that the authors suggest may have been due 
in part to the high placebo response evident in this trial. The 
secondary outcomes roughly mirrored the primary outcome. 
On the PANSS positive subscale score, asenapine 5 mg twice 
daily and haloperidol were superior to placebo from day 21 
onwards; asenapine 10 mg twice daily showed an advantage 
at day 42 and study endpoint. On the LOCF analysis of 
change in the PANSS negative subscale, none of the treat-
ments was superior to placebo. However, using MMRM, 
asenapine 5 mg twice daily demonstrated an advantage at 
days 35 and 42. On both the LOCF and MMRM analyses 
of change in the PANSS general psychopathology subscale 
score, asenapine 5 mg twice daily was superior to placebo 
from day 21 onwards, in contrast with haloperidol, which 
showed an advantage at day 21 only, and with asenapine 
10 mg twice daily, which showed no advantage at any time 
point. PANSS Marder factor scores were also determined, 
and on both the LOCF and MMRM analyses, all active Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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treatment regimens were superior to placebo on the positive 
factor, but none showed an advantage on the negative factor. 
On both analyses of the hostility/excitement factor, only 
haloperidol was superior to placebo. Asenapine 5 mg twice 
daily was the only intervention that demonstrated superior-
ity to placebo on the anxiety/depression factor (by MMRM) 
and the disorganized thought factor (by LOCF and MMRM). 
Categorical response, defined as a minimum decrease of 30% 
on the PANSS total score or a Clinical Global Impression-
Improvement (CGI-I) score of 1 (ie, very much improved) 
or 2 (much improved), were for PANSS 55%, 49%, 43%, 
and 33%, for asenapine 5 mg twice daily, asenapine 10 mg 
twice daily, haloperidol, or placebo, respectively, yielding 
a NNT = 5, 7, and 10 versus placebo for asenapine 5 mg 
twice daily, asenapine 10 mg twice daily, and haloperidol, 
respectively. Similarly, CGI-I responders at endpoint were 
48%, 44%, 44%, and 34%, for asenapine 5 mg twice daily, 
asenapine 10 mg twice daily, haloperidol or placebo, respec-
tively, yielding a NNT = 8, 10, and 10 versus placebo for 
asenapine 5 mg twice daily, asenapine 10 mg twice daily, 
and haloperidol, respectively. Using change in CGI-I change 
as the outcome of interest, asenapine 5 mg twice daily and 
haloperidol were both significantly superior to placebo from 
day 21 onwards (by LOCF and MMRM).
In the second short-term acute schizophrenia trial that 
was considered positive and supportive of asenapine, 182 
patients were randomized to asenapine 5 mg twice daily 
(titrated as 1 mg twice daily on day 1, 2 mg twice daily on 
day 2, 3 mg on day 3, 4 mg twice daily on day 4, and 5 mg 
on day 5), placebo, or an active control for assay sensitivity, 
ie, risperidone 3 mg twice daily (titrated as 1 mg twice daily 
on day 1, 2 mg twice daily on day 2, and 3 mg twice daily on 
day 3).4 The study took place in the US in 2001–2002. Patients 
were required to be hospitalized during the first three weeks 
of the study. The primary efficacy endpoint was change from 
baseline on the PANSS total score, and was analyzed using 
LOCF. Discontinuation rates were 54.2%, 57.6%, and 66.1% 
for asenapine, risperidone, and placebo groups, respectively. 
The discontinuation rates due to lack of efficacy were 15.2%, 
27.1%, and 29.0%, respectively, yielding a NNT = 8 versus 
placebo to avoid a discontinuation due to lack of efficacy for 
asenapine and 53 for risperidone. Compared with placebo, 
asenapine produced significantly greater decreases in PANSS 
total scores from week 2 onwards. Risperidone did not 
separate statistically from placebo. Compared with placebo, 
asenapine and risperidone were associated with significantly 
greater decreases in Clinical Global Impression-Severity 
(CGI-S) scores from week 4 onwards. On the PANSS positive 
subscale, scores with asenapine demonstrated statistically 
greater improvement over placebo for asenapine from week 
3 onwards, and with risperidone at weeks 1, 3, 5, and 6. On 
the PANSS negative and general psychopathology subscales 
at endpoint, asenapine demonstrated statistically superior 
improvement compared with placebo but risperidone did not. 
A post hoc MMRM analysis confirmed the overall efficacy 
of asenapine in the primary outcome measure. The authors 
The metric of number needed to treat (NNT), defined as the number of patients who need to be treated to achieve one additional favorable outcome, can help
clinicians appraise claims that one intervention is meaningfully superior to another. Number needed to harm is the analog  of NNT when referring to
unfavorable outcomes or outcomes that a clinician wants to avoid. 
Calculating NNT for an outcome for drug A versus drug B is as follows: 
fA = frequency of outcome for drug A 
fB = frequency of outcome for drug B 
Attributable risk (AR) = fA – fB
NNT = 1/AR 
By convention, NNT is rounded up to the next higher whole number. 
Example: 
Medications A and B are used to treat depression, and they result in eight-week remission rates of 35% and 55%, respectively. The NNT to encounter one
additional remitted patient at eight weeks when choosing drug B versus drug A is calculated as follows: 
Difference in remission rates = 0.55 − 0.35 = 0.20 
NNT = 1/0.20 = 5 
Figure 1 Number needed to treat.35Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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speculated on the reasons why risperidone may not have 
performed as expected, including issues regarding dosing at 
6 mg/day. Not mentioned in the study report, but available 
elsewhere,26 are the categorical response rates. Using the 
criterion of a PANSS score reduction in at least 30%, 38% of 
the patients in the asenapine group were responders compared 
with 39% in the risperidone group and 25% in the placebo 
group, yielding a NNT = 8 versus placebo for asenapine and 
NNT = 7 for risperidone.25
Longer-term efficacy
Longer-term studies are also available (Table 2). Published is 
a one-year double-blind study in 1225 patients with schizo-
phrenia or schizoaffective disorder who were randomized 
to asenapine (5 mg twice daily for the first week and then 
flexible dosing of 5 mg or 10 mg twice daily) or olanzap-
ine (10 mg/day for the first week and then flexible dosing 
of 10 mg/day or 20 mg/day).6 There was no placebo arm. 
The study was international in scope and was conducted in 
2003–2006. Both inpatients and outpatients were eligible to 
participate. The primary outcome measure as noted in the 
clinicaltrials.gov record was change in total PANSS score at 
endpoint.36 Discontinuation rates were 61.4% for asenapine 
and 42.8% for olanzapine. The discontinuation rates because 
of insufficient therapeutic effect were 25.1% for asenapine 
and 14.5% for olanzapine (NNT = 10 for olanzapine versus 
asenapine to avoid discontinuation because of insufficient 
therapeutic effect). In the LOCF analysis, changes from 
baseline in PANSS total score with asenapine and olanzapine 
were similar at week 6, but showed a statistically signifi-
cant difference in favor of olanzapine at endpoint. Among 
the patients who completed the year-long trial, changes in 
PANSS total score with asenapine and olanzapine were 
similar at week 6 and also at week 52. Categorical outcomes 
were provided for CGI-I scores; 66% of patients treated with 
olanzapine had an endpoint CGI-I of 1 or 2, compared with 
52% for asenapine (NNT = 8).
Efficacy for the maintenance phase of schizophrenia was 
demonstrated in a published 26-week placebo-controlled, 
double-blind, multicenter, clinical trial.5 Patients were 
randomized either to continue receiving asenapine or to 
receive placebo after having achieved stability on asenapine 
during 26 weeks of open-label treatment immediately prior. 
The study was conducted in the US during 2005–2008. The 
primary outcome measure was time to relapse/impending 
relapse (as determined by the investigator using specific 
criteria as well as specific scores on the PANSS and the 
CGI-S scale). Of the 700 enrolled patients who were treated 
with open-label asenapine, 386 met the stability criteria and 
were randomized. Times to relapse/impending relapse and 
discontinuation for any reason were significantly longer 
with asenapine than with placebo. The incidence of relapse/
impending relapse was 12.1% for asenapine and 47.4% for 
placebo (NNT = 3). Completion rates were 69.6% for asenap-
ine and 37.5% for placebo (NNT = 4). The most commonly 
used dose of asenapine was 10 mg twice daily in both the 
open-label and double-blind phases.
Asenapine was assessed over 52 weeks in an extension 
to the acute study that used haloperidol as an active control.3 
Although not yet published, some of the data are available.12,20 
Patients receiving active medication during the six-week 
trial were maintained on the same fixed-dose regimen dur-
ing week 1 of the extension, after which dosing was flexible 
(asenapine 5 mg or 10 mg twice daily, haloperidol 2–8 mg 
twice daily). Patients who had received placebo were given 
blinded asenapine (5 mg twice daily during week 1, flexible 
dosing at 5 mg or 10 mg twice daily thereafter). Of 272 
patients who completed the six-week trial, 187 entered the 
extension and 66 completed 58 weeks of treatment (placebo/
asenapine 20; asenapine 30; haloperidol 16). The primary 
outcome measure was loss of effect over time, as measured 
by loss of effect in subjects who had at least a 30% decrease 
from baseline in the PANSS score at the end of the original 
trial3 preceding the long-term extension. Loss of effect was 
defined as at least a 30% increase in the total PANSS score 
from the start of the extension study, subjective worsening 
of schizophrenia/request for dose increase, CGI-S of at 
least 6, or discontinuation for lack of efficacy. The numbers 
of subjects for this analysis were 30 for placebo/asenapine, 
65 for asenapine, and 29 for haloperidol. Actual treatment 
failure rates were similar during the 52-week extension: 
85% of asenapine patients and 90% of haloperidol patients 
demonstrated loss of treatment effect. The Kaplan–Meier 
estimate of loss of effect was 0.86 for placebo/asenapine, 0.88 
for asenapine, and 0.94 for haloperidol. Median survival time 
was 57 days for placebo/asenapine, 31 days for asenapine, and 
85 days for haloperidol. Mean changes in PANSS total score 
from baseline of the six-week trial (LOCF) for asenapine and 
haloperidol, respectively, were −23.7 versus −22.6 at baseline 
of the extension, −21.9 versus −26.5 at week 52, and −21.8 
versus −26.7 at study endpoint.
Persistent negative symptoms of schizophrenia were 
also studied in patients receiving asenapine.16,37 These 
unpublished studies consist of two identically designed 
randomized clinical trials where patients were randomized 
to receive flexible-dose asenapine (5 mg twice daily in week Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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1 and then 5 or 10 mg twice daily) or olanzapine (10 mg/day 
in week 1 and then 5–20 mg/day) for up to 26 weeks.18,38 
Corresponding 26-week double-blind extension studies 
were available to the completers, during which subjects 
were maintained on the treatment regimen used at the end 
of each core study, with no rerandomization.21,22 The primary 
outcome measure was change from core study baseline on 
the 16-item Negative Symptom Assessment (NSA-16) scale 
total score, analyzed using MMRM. Treatment differences 
on this outcome were observed only in the 26-week exten-
sion of a 26-week core study conducted in the Western 
hemisphere,18,21 and was reported in a conference abstract.9 
Completion rates for the entire 52 weeks were 66.3% for 
asenapine and 80.9% for olanzapine (NNT = 7). At week 
26 of the core study, NSA-16 total score changes with 
asenapine and olanzapine did not differ significantly, but 
at week 52, NSA-16 total score changes were significantly 
greater with asenapine (−15.8) versus olanzapine (−11.0). 
In another abstract,16 results from a post hoc pooled analysis 
of all four trials (ie, the two core trials and their respective 
extensions) were provided. A total of 949 participants were 
randomized to treatment in the two core studies (asenapine, 
485; olanzapine, 464). Of the 613 participants (asenapine, 
277; olanzapine, 336) who completed 26 weeks of treat-
ment, 502 (asenapine, 220; olanzapine, 282) entered the 
26-week extensions and 412 (asenapine, 170; olanzapine, 
242) completed an additional 26 weeks of treatment. 
Discontinuation rates due to lack of therapeutic effect 
(defined as worsening of schizophrenia as an adverse event 
plus lack of efficacy) was significantly greater for asenapine 
versus olanzapine for the first 26 weeks among all treated 
participants entering the core studies (13.6% versus 7.3%, 
NNT = 16), and among all subjects entering the extensions 
(5.5% versus 2.1%, NNT = 30). After 26 weeks of treatment, 
change from core study baseline in NSA-16 total score did 
not significantly differ between asenapine and olanzapine, 
but at 52 weeks the change from core study baseline in 
NSA-16 total score was significantly greater with asenapine 
than for olanzapine.
Meta-analysis
Presented at a conference was a meta-analysis,17 where data 
from all randomized head-to-head comparisons of asenapine 
with second-generation antipsychotics and published ran-
domized head-to-head comparisons of second-generation 
antipsychotics in the treatment of schizophrenia were 
analyzed. This permitted indirect comparisons. Change in 
PANSS total score at week 6 was significantly greater with 
asenapine than with placebo (LOCF, −3.7; MMRM −4.1). 
The efficacy of asenapine relative to placebo was compa-
rable with that of the combined active controls used in the 
studies (LOCF −4.1; MMRM −4.6). Analysis of PANSS 
responder rates (defined by an at least 30% decrease from 
baseline) revealed a NNT = 11 versus placebo and was 
comparable with responder rates of the combined active 
controls (NNT = 12). Estimated PANSS total score dif-
ference between asenapine and other second-generation 
antipsychotics ranged from 3.9 points better than ziprasi-
done to 2.9 points worse than olanzapine. Risperidone and 
amisulpride slightly outperformed asenapine (1.0 and 0.5 
points, respectively) but asenapine performed better than 
aripiprazole (1.6 points), quetiapine (1.1 points), sertindole 
(1.0 points), and clozapine (0.3 points).
Dosing
The product labeling recommends asenapine 5 mg twice 
daily as the starting and target dose when treating adult 
patients with acute schizophrenia,2 based on the pattern of 
results observed in the short-term clinical trials.25 In contrast, 
the most commonly used dose in the relapse/maintenance 
trial6 for both the open-label stabilization period and the 
randomized phase was 10 mg twice daily. In a modeling and 
simulation study,39 asenapine 5 mg and 10 mg twice daily 
doses had similar efficacy. The FDA has requested that a 
study be done that can identify the lowest effective dose of 
asenapine for the treatment of adults with schizophrenia (ie, 
a trial of a dose lower than 5 mg twice daily, such as 2.5 mg 
twice daily).25
Safety and tolerability
According to the product labeling,2 the most commonly 
encountered adverse events in patients with schizophrenia 
are listed as akathisia, oral hypoesthesia (numbness), and 
somnolence. Rates and number needed to harm (NNH) 
versus placebo are outlined in Table 3. Akathisia may be 
dose-related. The product labeling describes somnolence 
as usually transient, with the highest incidence reported 
during the first week of treatment.2 Rates for somnolence 
are higher in bipolar patients treated with asenapine, which 
may be reflective of the overall different doses of asenapine 
used in the treatment of manic or mixed episodes (usually 
10 mg twice daily), or the different sensitivity of patients 
with bipolar disorder to complain actively of somnolence. 
Although somnolence was frequently reported, somnolence/
sedation led to discontinuation in only a small proportion 
(0.6%) of patients treated with asenapine.2Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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A caveat is that these rates are that of spontaneously 
reported events. Patients in clinical trials may have a differ-
ent threshold for complaining about side effects than persons 
treated in real-world practice. Directly asking patients about 
adverse effects, such as oral hypoesthesia, may yield higher 
rates. In healthy male subjects from a Phase I study of 
asenapine 5 mg,29 the most common adverse events were oral 
paresthesia (sublingual, 75.8%; supralingual, 55.9%; buccal, 
45.7%) and somnolence (81.8%; 76.5%; 68.6%).
In the short-term study of asenapine with haloperidol as 
the active control,3 adverse events occurred in 44% and 52%, 
57%, and 41% of the asenapine 5 mg and 10 mg twice daily, 
haloperidol, and placebo groups, respectively. Extrapyramidal 
symptoms (in most cases rated as mild or moderate) reported 
as adverse events occurred in 15% and 18%, 34%, and 10% 
of the asenapine 5 mg and 10 mg twice daily, haloperidol, 
and placebo groups, respectively (NNH = 6 for haloperidol 
versus asenapine and NNH = 7 for asenapine 5 mg and 10 mg 
twice daily, respectively). During the study, antiparkinsonian 
medication was initiated in 17%, 19%, 12%, and 43% of 
patients in the asenapine 5 mg and 10 mg twice daily, placebo, 
and haloperidol groups, respectively (NNH = 4 for haloperi-
dol versus asenapine and NNH = 5 for asenapine 5 mg and 
10 mg twice daily, respectively). For akathisia specifically, 
rates were 5% and 12%, 15%, and 3% for the asenapine 5 mg 
and 10 mg twice daily, haloperidol, and placebo groups, 
respectively. Oral hypoesthesia was reported in 11% and 
9% with asenapine 5 mg and 10 mg versus 2% with placebo 
and 0% with haloperidol. Somnolence was reported in 9% 
and 8% of patients on asenapine 5 mg and 10 mg twice daily 
versus less than 1% with placebo and 2% with haloperidol. 
Across all groups, no more than 5% of patients had clinically 
significant weight change. Mean changes from baseline in 
levels of lipids, fasting glucose, and liver enzymes were small 
in all treatment groups and comparable with those seen with 
placebo. No patients in any treatment group had abnormal 
postbaseline total cholesterol levels. The percentages of 
patients with abnormal postbaseline fasting glucose levels 
were 1%, 2%, 1%, and 3% in the asenapine 5 mg and 10 mg 
twice daily, placebo, and haloperidol groups, respectively. 
From baseline to last assessment, prolactin levels decreased 
in the placebo group and both asenapine groups, but increased 
in the haloperidol group. The percentages of patients with 
abnormal postbaseline prolactin levels (greater than four 
times the upper limit of normal) were 4%, 5%, 2%, and 10% 
in the asenapine 5 mg and 10 mg twice daily, placebo, and 
haloperidol groups, respectively. Incidence rates of clinically 
relevant weight gain, defined as at least a 7% increase from 
baseline, were 5%, 4%, 2%, and 4% in the asenapine 5 mg 
and 10 mg twice daily, placebo, and haloperidol groups, 
respectively.
In the short-term study of asenapine with risperidone as 
the active control,4 adverse events occurred in 83%, 79%, 
and 90% of patients in the asenapine, placebo, and risperi-
done groups, respectively. The most frequently reported 
adverse events were insomnia, somnolence, nausea, anxiety, 
and agitation in the asenapine group; agitation, headache, 
anxiety, and dizziness in the placebo group; and insomnia, 
somnolence, anxiety, agitation, and headache in the risperi-
done group. Risperidone-treated patients were more likely to 
report symptoms resembling hypertonia (12% versus 0% for 
asenapine and 3% for placebo) and hyperkinesia (7% versus 
0% for asenapine and placebo) as adverse events, and more 
likely to use antiparkinsonian drugs (17%, 21% and 31%, for 
asenapine, placebo, and risperidone, respectively (NNH = 8 
for risperidone versus asenapine). The incidence of clinically 
relevant weight gain was 17.0% with risperidone versus 
4.3% with asenapine and 1.9% with placebo (NNH = 8 for 
risperidone versus asenapine). The proportion of patients with 
normal baseline prolactin levels but postbaseline levels at least 
twice the upper limit of normal was 79% for risperidone com-
pared with 9% for asenapine and 2% for placebo (NNH = 2 
for risperidone versus asenapine). Abnormal postbaseline 
fasting glucose levels occurred in 14%, 12%, and 20% of 
patients treated with asenapine, placebo, and risperidone, 
respectively. At least one postbaseline QTc interval of at least 
450 msec was observed in 9%, 10%, and 18% of patients 
treated with asenapine, placebo, and risperidone, respectively, 
but there were no reports of QT interval prolongation greater 
than 500 msec in any treatment group. Mean changes in QTc 
from baseline were +4.6 msec with asenapine, –1.6 msec with 
placebo, and +4.4 msec with risperidone.
Table 3 Commonly encountered (incidence $5% and two-fold 
greater than placebo for at least one of the doses) spontaneously 
reported adverse events as reported in product labeling for the 
acute treatment of schizophrenia: percentage of patients reporting 
reaction and number needed to harm versus placebo*
Adverse event Asenapine studies
Placebo Asenapine  
10 mg/day
Asenapine  
20 mg/day
Rate Rate NNH Rate NNH
Somnolence 7% 15% 13 13% 17
Akathisia 3% 4% 100 11% 13
Oral hypoesthesia 1% 6% 20 7% 17
Notes: *Data from Table 2 in product labeling for asenapine.2Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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A specially designed thorough 16-day QT study has 
been published.7,8 Patients were randomized to asenapine 
5 mg twice daily followed by 10 mg twice daily, asenapine 
15 mg twice daily followed by 20 mg twice daily, quetiapine 
375 mg twice daily, or placebo. At maximum plasma concen-
tration for all asenapine doses, the exposure-response model 
predicted a mean QTc increase of less than 5 msec. The model 
predicted a mean increase of 7–8 msec for quetiapine. The 
corresponding upper bounds of the 95% confidence intervals 
were 7.5 msec and 11.2 msec for asenapine and quetiapine, 
respectively. Using another modeling technique, QTc esti-
mates for asenapine were 7–10 msec.
Information about asenapine in elderly patients with 
psychosis is also available.10,11,23 An unpublished six-week 
randomized trial enrolled patients aged at least 65 years of age 
with psychotic symptoms (not related to dementia), defined 
as a PANSS score of at least 4 on at least one prespecified 
item (delusions, hallucinatory behavior, excitement, hostility, 
poor impulse control), a PANSS total score greater than 50, 
and a CGI-S score of at least 3. Asenapine was given in two 
treatment schedules, ie, two days at 2 mg twice daily, two 
days at 5 mg twice daily, and 10 mg twice daily thereafter 
(2–5–10); or four days at 5 mg twice daily and 10 mg twice 
daily thereafter (5–10). Drug treatment was conducted under 
double-blind conditions during the initial six days, and was 
open-label for the remainder of the trial. Primary outcomes 
were related to occurrences of adverse events as well as 
pharmacokinetic variables.23 The mean age of the subjects 
was 71 years. The completion rate was 62.3%. Tolerability 
was comparable across treatment schedules. The percentage 
of subjects who experienced an adverse event was 72% in 
each group. The percentage of subjects who discontinued 
because of an adverse event was 20% in the 2–5–10 titration 
group and 15% in the 5–10 titration group. The rate of seri-
ous adverse events was 10% for the 2–5–10 titration group 
and 5% for the 5–10 titration group. Adverse events reported 
by at least 5% of patients included hypertension (8.2%), 
headache (6.6%), and somnolence (6.6%), and the incidence 
of extrapyramidal-related adverse events was 5.7%. Mean 
weight change at endpoint was 0.4 kg; clinically significant 
weight gain was reported in two patients (1.6%).
Data about the longer-term tolerability of asenapine 
is available from the longer-term studies. In the relapse/
maintenance study,5 the most frequently reported adverse 
events with asenapine versus placebo during the double-blind 
phase were anxiety (8.2% versus 10.9%), increased weight 
(6.7% versus 3.6%), and insomnia (6.2% versus 13.5%). 
Anxiety and insomnia after being switched to placebo from 
asenapine can be logically anticipated because patients 
were required to demonstrate stability on asenapine prior to 
randomization. The incidence of clinically relevant weight 
gain was 3.7% with asenapine versus 0.5% with placebo. 
Mean changes in scales measuring extrapyramidal symptoms 
were similar with asenapine and placebo.
Of greater clinical relevance than long-term comparisons 
of asenapine with placebo are comparisons of asenapine with 
other antipsychotics. In a one-year, double-blind, randomized 
controlled trial comparing asenapine with olanzapine,6 the 
incidence of treatment-emergent adverse events was 82% 
in both groups. Most reported adverse events were rated as 
mild or moderate. For the asenapine and olanzapine groups, 
respectively, incidence rates of treatment-emergent serious 
adverse events were 19% and 12% (NNH = 15), and rates 
of treatment-related serious adverse events were 6% and 2% 
(NNH = 25). The mortality rate was less than 1% in both 
groups, and none were considered treatment-related per 
se; there were seven deaths in the asenapine group (five by 
suicide, among 11 attempts) and one death in the olanzapine 
group (by suicide, among six attempts). Mean weight gain 
was 0.9 kg with asenapine and 4.2 kg with olanzapine. The 
proportion of patients experiencing clinically relevant weight 
gain was approximately 35% for olanzapine and approxi-
mately 15% for asenapine (NNH = 5). No notable changes 
or between-group differences were seen in measures of total 
cholesterol or glucose, but triglyceride levels rose substan-
tially with olanzapine and declined slightly with asenapine. 
Extrapyramidal symptoms reported as adverse events 
were more common with asenapine (18%) compared with 
olanzapine (8%, NNH = 10). The most commonly reported 
type of movement disorder in the asenapine and olanzapine 
groups was akathisia, with treatment-emergent rates of 
10% for asenapine and 4% for olanzapine (NNH = 17). 
Extrapyramidal symptoms, most commonly akathisia, were 
the reported cause of premature discontinuation in 12 patients 
taking asenapine (1%) and three patients taking olanzapine 
(1%). Anticholinergic drug use among all treated patients 
at endpoint was 6% for asenapine and 2% for olanzapine 
(NNH = 25). On formal assessment of extrapyramidal 
symptoms, mean scores on rating scales decreased from 
baseline in both groups. Markedly abnormal increases (to 
levels greater than three times the upper limit of normal) 
in alanine transaminase were seen in 3% of the asenapine 
group and 11% of the olanzapine group (NNH = 13); for 
aspartate transaminase, the percentages were 1% and 3%, 
respectively (NNH = 50). The incidence of abnormalities 
in vital signs was low and not different between the groups. Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Electrocardiographic abnormalities, mostly QT prolongation, 
were observed in 2.4% and 1.3% of patients in the asenapine 
and olanzapine groups, respectively (NNH = 91); however, 
there were no instances of QTc of $500 msec at any time 
during treatment.
An unpublished two-year blinded extension to the 
above study was also completed, providing three years of 
data.13,14 Of the 440 enrolled patients, 114 discontinued; 
rates of discontinuation were 30% for asenapine and 18% 
for olanzapine (NNT = 9). The most common reasons for 
discontinuation were withdrawal of consent (asenapine, 
11.0%; olanzapine, 12.7%) and treatment-emergent adverse 
events (asenapine, 10.3%; olanzapine, 2.0%). Mean weight 
gain from core study baseline was 1.6 kg with asenapine 
and 5.0 kg with olanzapine, and the incidence of clini-
cally relevant weight gain was 28% and 40%, respectively 
(NNH = 9). The incidence of extrapyramidal symptom 
adverse events during the entire treatment period was 20% 
with asenapine and 11% with olanzapine (NNH = 12), and 
during the extension alone was 4.5% and 3.3%, respectively 
(NNH = 84).
Safety and tolerability data are available from the 
52-week extension to the acute study that used haloperidol 
as an active control.12,20 From the baseline of the six-week 
trial to the end of the extension, incidence rates of treatment-
emergent adverse events were 88%, 85%, and 86% for 
placebo/asenapine, asenapine, and haloperidol, respectively. 
The most common treatment-emergent adverse events 
not related to worsening of schizophrenia in the placebo/
asenapine, asenapine, and haloperidol groups were insomnia 
(38%, 32%, 21%), parkinsonism (10%, 17%, 28%), akath-
isia (10%, 16%, 28%), and headache (26%, 16%, 19%). 
The incidence of clinically relevant weight gain was 13%, 
19%, and 15%. Extrapyramidal symptom adverse events 
was higher with haloperidol (54%) than with placebo/
asenapine (18%) or asenapine (35%) (NNH = 6 for halo-
peridol versus asenapine). Mean changes in prolactin levels 
were −10.8, −13.8, and −23.7 µg/L for placebo/asenapine, 
haloperidol, and asenapine, respectively. The incidence of 
markedly abnormal results on fasting glucose, hemoglobin 
A1c, cholesterol, and triglycerides was low, with no notable 
between-group differences. Two deaths occurred (one each 
with asenapine and haloperidol), and neither was considered 
treatment-related.
Safety information is available from the studies examin-
ing negative symptoms in schizophrenia but these studies 
have not yet been published and thus their results have only 
been partially disclosed. In one of the extension studies that 
was presented at a meeting,9 the incidence of treatment-
emergent adverse events was 82% with asenapine and 91% 
with olanzapine (NNH = 12). The incidence of extrapyra-
midal adverse events was 24% for asenapine and 10% for 
olanzapine (NNH = 8). Weight changes from core study 
baseline to week 52 were 1.2 kg for asenapine and 2.2 kg 
for olanzapine.
A pooled analysis of weight change and metabolic 
effects of asenapine has also been presented.15 A database 
of 1748 patients who participated in trials that included a 
placebo control (989 receiving asenapine and 759 receiving 
placebo) and 3430 patients who participated in trials that 
included an olanzapine control (2067 receiving asenapine 
and 1363 receiving olanzapine) were included among 
13 schizophrenia and four bipolar disorder trials, short-term 
and long-term, including extensions. Of note, four trials 
(two in patients with schizophrenia and two in patients 
with bipolar disorder) included both placebo controls and 
olanzapine controls. In 15 of the 17 trials, asenapine doses 
were 5 mg or 10 mg twice daily. Olanzapine doses were 
5–20 mg/day. For the placebo-controlled trials, asenapine 
exposure was at a mean dose of 16.2 mg/day with a mean 
treatment duration of 25.1 days. Mean exposure to placebo 
was for 24.8 days. For the olanzapine-controlled studies, 
asenapine exposure was at a mean dose of 15.3 mg/day 
with a mean treatment duration of 207.3 days. Olanzapine 
exposure was at a mean dose of 15.0 mg/day with a mean 
treatment duration of 226.2 days. At endpoint, the mean 
weight change with asenapine was significantly greater 
than with placebo (1.2 kg versus 0.1 kg) and significantly 
less than with olanzapine (0.9 kg versus 3.1 kg). Mean 
change in total cholesterol, low-density lipoprotein, and 
high-density lipoprotein at endpoint was not significantly 
different between asenapine and placebo. Mean change in 
triglycerides differed significantly for asenapine versus 
placebo (1.8 mg/dL versus −12.2 mg/dL). Percentages of 
patients with clinically relevant lipid changes in categori-
cal analyses tended to be higher with asenapine than with 
placebo, with the exception of low-density lipoprotein, 
for which no differences were seen. Mean change was 
significantly lower with asenapine than with olanzapine 
for total cholesterol (−0.4 mg/dL versus 6.2 mg/dL), 
low-density lipoprotein (−0.3 mg/dL versus 3.1 mg/dL), 
and fasting triglycerides (−0.9 mg/dL versus 24.3 mg/dL). 
Mean change in high-density lipoprotein was signifi-
cantly greater with asenapine than olanzapine (1.3 mg/dL 
versus −0.2 mg/dL). At endpoint, mean change in fasting 
glucose was significantly higher for asenapine versus Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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placebo (1.9 mg/dL versus −1.6 mg/dL) but was numerically 
lower for asenapine versus olanzapine (2.0 versus 
3.3 mg/dL). Although the abstract states that categorical 
outcomes when comparing asenapine versus placebo gener-
ally reflect the mean changes in the variables mentioned, 
the actual values are not provided.
Other outcomes
The controlled clinical trials available provide limited infor-
mation regarding potential changes in outcomes other than 
psychotic symptoms. In one of the short-term trials, second-
ary outcomes included the Calgary Depression Scale for 
Schizophrenia (CDSS), the Modified International Suicide 
Prevention Trial (InterSePT) Scale for Suicidal Thinking, 
and the Readiness to Discharge Questionnaire (RDQ).3 
On LOCF analysis of change in CDSS score, significant 
improvement was seen with asenapine at 5 mg twice daily 
starting at day 21; no statistically significant advantage over 
placebo was observed with asenapine 10 mg twice daily or 
haloperidol. On the Modified InterSePT Scale for Suicidal 
Thinking and the RDQ, changes from baseline to endpoint 
were small in all groups, and no active treatment showed 
a significant difference from placebo. In a Kaplan–Meier 
analysis, 50% of patients were ready for discharge on day 
15 with asenapine 5 mg twice daily and haloperidol, on 
day 16 with asenapine 10 mg twice daily, and on day 20 
for placebo.
In the one-year study comparing asenapine with 
olanzapine,6 increases in mean Subjective Well-being under 
Neuroleptic treatment scale scores were observed for both 
asenapine and olanzapine. However, no relevant change 
from baseline was observed on either the mental or physi-
cal component of the 12-item Short Form scale, suggest-
ing to the authors that patients’ overall health status was 
not notably affected by treatment with either asenapine or 
olanzapine. Moreover, there were no notable changes within 
groups or significant between-group differences in living 
situation, employment, or level of functioning. Among the 
outpatient subjects in the trial, hospitalization occurred in 
6% of those on asenapine and 3% in those on olanzapine 
(NNH = 34). However, the total number of hospital days 
during the trial was marginally lower for asenapine than 
for olanzapine (mean 34.9 days and 36.3 days, respec-
tively). In terms of preferences and ranking, at study end, 
34% of asenapine-treated patients and 37% of investi-
gators considered asenapine much better than previous 
antipsychotic medication; corresponding percentages for 
olanzapine were 40% and 48%, respectively. Quality of life 
scale changes was recorded in the extension to the Western 
hemisphere study comparing asenapine with olanzapine for 
patients with predominantly negative symptoms;9 improve-
ment was noted in both treatment arms, with no relevant 
between-group differences, as was also observed in the 
parent study.18
The market uptake of asenapine was reported in a brief 
paper.40 Postlaunch retail prescription trends of asenapine 
were assessed. In the 12 months since launch, asenapine 
gained a 0.22% share of the second-generation antipsychotic 
market. The share of new patient prescriptions was 0.44%; 
this is double the total market share and may be a predic-
tor of future growth. About 77% of total prescriptions of 
asenapine were generated by psychiatrists; this is higher than 
that for other second-generation antipsychotics. From the 
data reported in the study, it is unknown what proportion of 
asenapine prescriptions were for patients with schizophrenia 
versus those with bipolar disorder.
Conclusion
Selecting the “right” antipsychotic for the “right” patient is 
complex, and can involve trial and error. Factors in treat-
ment selection include prior history of therapeutic response, 
prior history of tolerability with other agents, and individual 
patient values and preferences regarding both the symptoms 
to be targeted and the side effects to be avoided. Adherence 
can be the biggest obstacle to success; lack of consistent 
adherence is not uncommon in patients with schizophrenia, 
who may not perceive themselves as being ill or otherwise 
see no value in the medications being offered. Nonetheless, 
given the considerable heterogeneity in antipsychotic efficacy 
and tolerability among the available choices, as well as large 
individual variation in treatment response, having different 
options in order to optimize efficacy and tolerability for the 
individual patient is definitely desirable.1
Asenapine’s efficacy in the treatment of schizophrenia 
is evidenced in both short-term acute clinical trials and in 
longer-term studies. Although a dose of 5 mg twice daily 
was found to be efficacious in the acute trials, the 26-week 
maintenance trial was flexibly dosed, and the modal dose 
of asenapine was 10 mg twice daily both in the open-label 
stabilization phase and in the randomized phase. In the 
head-to-head 52-week study comparing asenapine with 
olanzapine, changes from baseline in PANSS total score with 
asenapine and olanzapine were similar at week 6, but showed 
a statistically significant difference in favor of olanzapine at Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
337
Sublingual asenapine for schizophrenia
endpoint (by LOCF). For observed cases (ie, patients who 
completed the entire study) changes in PANSS total score 
with asenapine and olanzapine were similar at week 6 and 
also at week 52.
In the mind of the clinician, comparisons of asenapine 
will likely be made against other “metabolically-friendly” 
second-generation antipsychotics, such as ziprasidone, arip-
iprazole, iloperidone, and lurasidone.41 Tradeoffs among the 
choices include issues such as once-daily versus twice-daily 
dosing, the need for dose titration, special requirements for 
administration with or without food, as well as specific side 
effect profiles (see also Table 4 in a paper by the author41 and 
Table 4 in another paper by the author42). Relative efficacy 
rankings among these five agents (asenapine, ziprasidone, 
aripiprazole, iloperidone, and lurasidone) are not known, 
and will require specifically designed and adequately 
powered head-to-head studies. Head-to-head comparisons 
with the older second-generation antipsychotics, such as 
quetiapine and risperidone, would also be of interest, as 
well as an expansion of work already being done comparing 
asenapine with olanzapine. In the meantime, meta-analyses 
can be performed that can indirectly estimate potential 
differences,17 as has been done with the older second-
generation antipsychotics.43–45
Available so far are the results of carefully conducted con-
trolled trials that enrolled patients who fulfilled strict inclu-
sion and exclusion criteria. All studies have been conducted 
by its manufacturer. The different studies for asenapine that 
examined acute use, maintenance use, and negative symp-
toms targeted somewhat different populations. These research 
subjects can be dissimilar to patients commonly treated in a 
routine clinical environment, particularly in terms of sever-
ity of illness, physical and psychiatric comorbidities (such 
as substance use), concomitant use of other antipsychotic 
medications, or dangerous behaviors. Known nonresponders 
to antipsychotics and patients recently treated with clozapine 
are commonly also excluded from participation in registra-
tion trials. There is a clear need for pragmatic clinical trials 
with more liberal enrollment criteria (permitting greater 
generalizability) that can help place antipsychotics such as 
asenapine into clinical perspective. Also desirable would 
be specific studies to ascertain the efficacy and tolerability 
profiles of asenapine in patients during their first episode of 
schizophrenia.
Asenapine remains unique as being the only antipsychotic 
that is absorbed in the oral mucosa. This renders impossible 
the surreptitious “cheeking” that can occur among patients 
who have an ambivalent attitude about adherence. Although 
asenapine is reasonably well tolerated, the possibility of oral 
hypoesthesia may be a new event for the patient, necessitat-
ing advance warning that this can occur. In the clinical trial 
program itself, oral hypoesthesia rarely led to discontinua-
tion from the clinical trial (observed in 7⁄2251 or 0.3% for 
asenapine versus 0% for all other groups).26 Dysgeusia (dis-
torted or bad taste), has largely been alleviated with a black 
cherry-flavored formulation of asenapine.
In summary, the place of asenapine in the treatment of 
schizophrenia is likely to be for patients in whom metabolic 
concerns are important, and for patients who would prefer 
a sublingual preparation. Specific obstacles to the first-line 
use of asenapine are the recommendations for twice-daily 
versus once-daily administration and the recommendation 
to avoid food or liquids for 10 minutes after dosing. Cost 
may be a further impediment, given the availability of 
inexpensive generic versions of risperidone in the US, as 
well as other generic second-generation antipsychotics in 
other countries.
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